Mark Jason H. Ellison
Director/Miembro de la Junta en Phax Pharma Consultants .
Perfil
Mark Jason H.
Ellison is currently the Director at Phax Pharma Consultants and a Member at GPhC.
He was previously the Chief Development Officer at Opiant Pharmaceuticals, Inc. from 2020 to 2023 and the Head-Technical Affairs at S.L.A.
Pharma AG from 2010 to 2014.
Ellison holds a doctorate degree from the University of Sunderland and an undergraduate degree from the University of Portsmouth.
Cargos activos de Mark Jason H. Ellison
| Empresas | Cargo | Inicio |
|---|---|---|
| GPhC | Corporate Officer/Principal | - |
| Phax Pharma Consultants | Director/Miembro de la Junta | - |
Antiguos cargos conocidos de Mark Jason H. Ellison.
| Empresas | Cargo | Fin |
|---|---|---|
| OPIANT PHARMACEUTICALS, INC. | Corporate Officer/Principal | 02/03/2023 |
S.L.A. Pharma AG
 S.L.A. Pharma AG BiotechnologyHealth Technology S.L.A. Pharma AG engages in the manufacture of pharmaceutical products. It specializes in development of medicines for the prevention and treatment of gastrointestinal disorders. The company was founded in 1997 and is headquartered in Liestal, Switzerland. | Director Técnico/Científico/I+D | 01/01/2014 |
Formación de Mark Jason H. Ellison.
| University of Portsmouth | Undergraduate Degree |
| University of Sunderland | Doctorate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas privadas | 4 |
|---|---|
Opiant Pharmaceuticals, Inc.
 Opiant Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Opiant Pharmaceuticals, Inc. is a pharmaceutical company, which engages in the development of pharmaceutical solutions for common addictions and related disorders. The firm focuses on developing treatment to reverse opioid overdoses, treatment for overweight and obese patients with binge eating disorder and treatment for patients with Bulimia Nervosa. Its principal product Naloxone is a medicine which is available through injection can reverse the overdose of prescription and illicit opioids. The company was founded on June 21, 2005 and is headquartered in Richmond, VA. | Health Technology |
S.L.A. Pharma AG
S.L.A. Pharma AG BiotechnologyHealth Technology S.L.A. Pharma AG engages in the manufacture of pharmaceutical products. It specializes in development of medicines for the prevention and treatment of gastrointestinal disorders. The company was founded in 1997 and is headquartered in Liestal, Switzerland. | Health Technology |
| GPhC | |
| Phax Pharma Consultants |
- Bolsa de valores
- Insiders
- Mark Jason H. Ellison
